Education
About Us
Working with TipRanks
Follow Us
Xenon (XENE)
NASDAQ:XENE
Earnings Data
Report Date
Aug 07, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.99Last Year’s EPS
-0.75Same Quarter Last Year
Strong Buy
Based on 15 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 12, 2025
|% Change Since: -11.02%
|Next Earnings Date:Aug 07, 2025
Earnings Call Sentiment|Positive
The earnings call indicated significant progress across Xenon's pipeline, particularly with azetukalner in epilepsy and MDD. Financially, the company is well-positioned to support ongoing developments. Despite a slight delay in the X-TOLE2 study and a negative primary endpoint in the MDD study, the overall sentiment remains positive due to consistent progress and strong financial backing.Company Guidance
During the Q1 2025 Xenon Pharmaceuticals Earnings Conference Call, the company provided guidance on several key metrics. Xenon is nearing the completion of patient recruitment for the X-TOLE2 Phase 3 study in epilepsy, with top-line results expected in early 2026. Despite a slight delay in recruitment, the company remains confident due to the consistency of key metrics with their successful Phase 2b study. Xenon anticipates having sufficient cash to fund operations into 2027, thanks to their strong fiscal management. The company is also expanding its neuroscience-focused pipeline, with multiple regulatory filings expected this year, and is preparing for the initiation of first-in-human trials for several new drug candidates. Additionally, Xenon's azetukalner has shown promising results in both epilepsy and major depressive disorder (MDD), with ongoing Phase 3 trials in MDD and plans to initiate trials in bipolar depression by mid-year.Progress in Azetukalner Phase 3 Epilepsy Program
Patient recruitment for the X-TOLE2 study is nearing completion with top-line results anticipated early next year. The study metrics align consistently with the successful Phase 2b X-TOLE study.
Extension of Azetukalner Usage Beyond Epilepsy
Enrollment is ongoing in the first phase 3 MDD study, X-NOVA2, with the second MDD study, X-NOVA3, and the first Phase 3 study in bipolar depression on track to initiate by mid-year.
Investigator-Sponsored MDD Study Results
The study results are consistent with prior expectations, showing clear drug activity on MADRS and SHAPS, reaffirming the rationale for further development in MDD.
Financial Position and Revenue Recognition
Xenon recognized revenue of $7.5 million from a milestone payment. Cash and cash equivalents stood at $691.1 million, sufficient to fund operations into 2027.
XENE Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
XENE Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 12, 2025 | $35.85 | $29.60 | -17.43% |
Feb 27, 2025 | $38.31 | $37.02 | -3.37% |
Nov 12, 2024 | $43.39 | $41.97 | -3.27% |
Aug 08, 2024 | $41.01 | $39.70 | -3.19% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Xenon (XENE) report earnings?
Xenon (XENE) is schdueled to report earning on Aug 07, 2025, TBA Not Confirmed.
What is Xenon (XENE) earnings time?
Xenon (XENE) earnings time is at Aug 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is XENE EPS forecast?
XENE EPS forecast for the fiscal quarter 2025 (Q2) is -0.99.